Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
With
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Boehringer Ingelheim
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults ≥18 years on maintenance hemodialysis (HD) with residual kidney function
Thrice-weekly HD
Willingness and capacity to provide informed consent
For women of childbearing potential, a negative pregnancy test is required at screening
You may not be if
Does not have capacity to consent
Anuria (daily urine volume \< 200 mL/day)
Planned kidney transplant within 3 months
Recurrent urinary tract infections (\>2 episodes/year or antibiotic prophylaxis)
New York Heart Association (NYHA) Class IV heart failure (HF)
Myocardial infarction, unstable angina, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 12 weeks
History of diabetic ketoacidosis
Type 1 Diabetes Mellitus
Hereditary glucose-galactose malabsorption or primary renal glucosuria
Liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis); Alanine aminotransferase (ALT) levels \>2.0 times the upper limit of normal (ULN) or total bilirubin \>1.5 times the ULN, unless consistent with Gilbert's disease
Active malignancy (exceptions: squamous and basal cell carcinomas of the skin and carcinoma of the cervix in situ) defined as malignancy under active treatment with chemotherapy, radiation or immunotherapy, or being treated as palliative.
Major surgery within 12 weeks
Atraumatic amputation within past 12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening
Combination use of angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB)
Current use of an SGLT2 inhibitor (within 6 weeks prior to randomization)
Known allergies, hypersensitivity, or intolerance to SGLT2i or its excipients
Received an active investigational drug (including vaccines) other than a placebo agent, or used an investigational medical device within 12 weeks before Day 1/baseline
Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study
Women of childbearing potential not willing to use a highly-effective method(s) of birth control, or who are unwilling or unable to be tested for pregnancy.
Any condition that in the opinion of the investigator would make participation not in the best interest of the subject